Full Press Release Details
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial.
BIIB
Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial
Key Takeaway: Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial